Two additional articles investigated the expenditure feasibility of ICI-based treatments, specifically pembrolizumab or nivolumab, for non-small cell lung cancer (NSCLC), revealing that these interventions were more cost-effective among PD-L1 ≥ 50% patients than PD-L1 ≥ 1% or 20% patients [39, 40]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.